Financing reflects strong investor confidence and supports advancement of lead Type 1 Diabetes program
ZURICH, Switzerland, April 01, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage biopharmaceutical company developing stem cell-based therapies for Type 1 Diabetes, today announced that it has entered into securities purchase agreements for a private placement at a purchase price of $2.75 per share, representing a 30% premium to the last closing price of the Company's common shares on March 31, 2026.
Pursuant to the terms of the securities purchase agreements, the Company is selling an aggregate of 490,907 common shares (and common share equivalents) and one series of warrants to purchase an aggregate of 687,270 common shares at an exercise price of $3.025 per share.
The offering includes participation from existing shareholders and is expected to close on or about April 15, 2026, subject to the satisfaction of customary closing conditions.
The Company intends to use the net proceeds from the offering, together with its previously announced $25 million equity line, to advance NCEL-101, NewcelX's lead program for Type 1 Diabetes, in collaboration with Eledon Pharmaceuticals, its other development pipeline programs, working capital and general corporate purposes.